2026-10-14T12:54:35Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33938178 2026-09-18T17:37:38Z category_13 category_21 category_46 category_734 category_61 category_64 category_106 portal_5 item_type_3 month_year_09_2026

<p>BSI and FACED scores.</p> Joshua De Soyza (24121959) Paul Ellis (6758159) Daniella Spittle (25073274) Anita Pye (17896389) Alice M. Turner (7950329) Genetics Biotechnology Immunology Biological Sciences not elsewhere classified Developmental Biology Cancer Science Policy minor adjustments reflecting mean age 54 larger multicentre datasets findings provide evidence 05 &# 8211 severe disease respectively severity score derived sectional data collection general bronchiectasis populations bronchiectasis severity index hazard ratio 1 1 antitrypsin deficiency lung function decline div >< p although prospective validation birmingham aatd registry cause bronchiectasis cohorts 1 %, 7 median bsi score 7 %, 23 severe aatd genotypes severe genotypes 7 %, cause bronchiectasis sgrq score clinical data 7 years confirmed bronchiectasis 4 %, ci 1 bsi score zz genotype study aimed specifically evaluated significant association sgrq ). related quality prognostic tool male ), increasingly recognised greater decline gas transfer alternative causes 8 %. 14 ). 002 ). 001 ), <div><p>Bronchiectasis is increasingly recognised in patients with alpha-1 antitrypsin deficiency (AATD), yet prognostic tools validated in general bronchiectasis populations have not been specifically evaluated in this group. The Bronchiectasis Severity Index (BSI) is a widely used multidimensional score predicting mortality, hospitalisation, and exacerbations in all-cause bronchiectasis. This study aimed to validate the BSI in a cohort of patients with AATD-bronchiectasis. Clinical data were obtained from the Birmingham AATD registry. Patients with severe AATD genotypes and CT-confirmed bronchiectasis were included, while those with non-severe genotypes or alternative causes of bronchiectasis were excluded. BSI scores were calculated using available registry data with minor adjustments reflecting the limitations of cross-sectional data collection. Associations between BSI and mortality were assessed using Kaplan–Meier survival analysis and Cox proportional hazards models adjusted for COPD, smoking status, and sex. Secondary analyses evaluated associations between BSI and lung function decline (FEV₁ and KCO) and health-related quality of life (SGRQ). A total of 198 patients were included (mean age 54.3 ± 9.7 years; 53.5% male), the majority with the ZZ genotype (97.5%) and coexisting COPD (87.4%). Median BSI score was 5 (range 0–14). Mortality differed significantly across BSI severity groups (p < 0.001): estimated 1-year mortality was 1.1%, 7.4%, and 20.0% for mild, moderate, and severe disease respectively, while 4-year mortality was 5.7%, 23.7%, and 31.8%. In Cox regression analysis adjusted for COPD, smoking, and sex, BSI remained significantly associated with mortality (hazard ratio 1.13 per point increase; 95% CI 1.05–1.23; p = 0.002). BSI score was also associated with greater decline in gas transfer (KCO) (β = −0.22% per point per year; p < 0.001), but showed no significant association with FEV₁ decline or SGRQ score. The Bronchiectasis Severity Index is associated with mortality risk in patients with AATD-associated bronchiectasis, supporting its use as a prognostic tool in this population. These findings provide evidence that a severity score derived from all-cause bronchiectasis cohorts can be applied to AATD, although prospective validation in larger multicentre datasets is warranted.</p></div> 2026-09-18T17:37:31Z Dataset Dataset 10.1371/journal.pone.0355956.t001 https://figshare.com/articles/dataset/_p_BSI_and_FACED_scores_p_/33938178 CC BY 4.0